Cardlytics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	2.1yrs
Board average tenure	1.2yrs

Recent management updates

Recent updates

CEO

Cardlytics has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Alexis DeSieno	Chief Financial Officer	1.3yrs	US$5.35m	0.23% $ 400.7k
Amit Gupta	COO & GM of Bridg	1.8yrs	US$2.66m	0.35% $ 614.1k
Nick Lynton	Chief Legal & Privacy Officer and Secretary	2.3yrs	US$1.06m	0.17% $ 293.9k
Peter Chan	Chief Technology Officer	3.4yrs	no data	no data
Peter Davies	Head of Sales Strategy & Operations	4.3yrs	no data	no data
Carson Napps	Chief People Officer	1.4yrs	no data	no data
Jose Singer	Chief Product Officer	2.5yrs	no data	no data
Evelyne Forester	Chief Business Officer	1.2yrs	no data	no data

2.1yrs

Average Tenure

41yo

Average Age

Experienced Management: 0LEC's management team is considered experienced (2.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Scott Hill	Independent Director	1.2yrs	US$132.77k	0.092% $ 160.8k
Liane Hornsey	Independent Director	less than a year	no data	0.020% $ 34.4k
John Klinck	Independent Chairperson of the Board	8.1yrs	US$216.85k	0.13% $ 232.5k
Andre Fernandez	Independent Director	less than a year	no data	no data
Jessica Jensen	Independent Director	4.3yrs	US$205.00k	0.076% $ 132.8k
Srishti Gupta	Director	less than a year	no data	no data
Aimée Lapic	Independent Director	5.6yrs	US$210.00k	0.084% $ 147.6k
Jonathan Francis	Independent Director	less than a year	no data	no data
Alex Mishurov	Independent Director	1.2yrs	no data	0.25% $ 435.2k

1.2yrs

Average Tenure

55yo

Average Age

Experienced Board: 0LEC's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.

Cardlytics Management

Management criteria checks 1/4

Key information

Recent management updates

Independent Director recently bought US$143k worth of stock

Cardlytics, Inc., Annual General Meeting, May 23, 2024

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

High number of new directors

Cardlytics, Inc. Announces Resignation of Tony Weisman as Member of the Board and as Member of the Nominating and Corporate Governance Committee

Recent updates

Now 21% overvalued after recent price rise

Third quarter 2024 earnings released: US$2.90 loss per share (vs US$0.63 loss in 3Q 2023)

Cardlytics, Inc. Reports Unaudited Consolidated Impairment of Goodwill and Intangible Assets for the Three Months Ended September 30, 2024

Cardlytics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

No longer forecast to breakeven

Independent Director recently bought US$143k worth of stock

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.087 loss per share (vs US$0.67 loss in 2Q 2023)

Cardlytics, Inc. Provides Earnings Guidance for the Third Quarter 2024

Cardlytics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

First quarter 2024 earnings released: US$0.56 loss per share (vs US$0.41 profit in 1Q 2023)

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Cardlytics, Inc. to Report Q1, 2024 Results on May 08, 2024

Cardlytics, Inc., Annual General Meeting, May 23, 2024

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

Now 36% undervalued

Cardlytics, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Cardlytics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Cardlytics, Inc. Provides Earnings Guidance for the First Quarter of 2024

Full year 2023 earnings released: US$3.69 loss per share (vs US$13.92 loss in FY 2022)

No longer forecast to breakeven

Cardlytics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

High number of new directors

Kigo, LLC acquired HSP EPI Acquisition, LLC from Cardlytics, Inc. (NasdaqGM:CDLX).

Cardlytics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Third quarter 2023 earnings released: US$0.63 loss per share (vs US$0.19 profit in 3Q 2022)

Cardlytics, Inc. Announces Resignation of Tony Weisman as Member of the Board and as Member of the Nominating and Corporate Governance Committee

Cardlytics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Cardlytics, Inc. Appoints Alex Mishurov as Independent Director

CEO & Director recently sold US$2.9m worth of stock

Cardlytics, Inc. Announces Board Member Changes

Insider recently sold US$172k worth of stock

Cardlytics, Inc. Provides Earnings Guidance for the Third Quarter 2023

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$3.76 loss in 2Q 2022)

No longer forecast to breakeven

Insufficient new directors

Cardlytics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Cardlytics Appoints Alexis Desieno as New Chief Financial Officer

Cardlytics, Inc. Announces Board Changes

Cardlytics, Inc. Announces Board Changes

First quarter 2023 earnings released: EPS: US$0.41 (vs US$0.98 in 1Q 2022)

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2023

Full year 2022 earnings released: US$13.92 loss per share (vs US$3.99 loss in FY 2021)

Cardlytics, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Cardlytics Appoints Amit Gupta as Chief Operating Officer

Cardlytics, Inc. Announces Board Changes

Third quarter 2022 earnings released: EPS: US$0.19 (vs US$1.35 loss in 3Q 2021)

Cardlytics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Cardlytics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Co-Founder & Executive Chairman recently sold US$141k worth of stock

Second quarter 2022 earnings released: US$3.76 loss per share (vs US$1.44 loss in 2Q 2021)

Cardlytics, Inc. Announces Consolidated Impairment Charge for the Second Quarter Ended June 30, 2022

Cardlytics Provides Revenue Guidance for the Quarter Ended June 30, 2022

Cardlytics, Inc. Provides Revenue Guidance for the Second Quarter Ended June 30, 2022

Cardlytics, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Cardlytics, Inc.(NasdaqGM:CDLX) dropped from Russell 2000 Growth Index

Cardlytics, Inc. Announces Executive Changes

Chief Financial Officer recently sold US$320k worth of stock

No longer forecast to breakeven

First quarter 2022 earnings released: EPS: US$0.98 (vs US$0.85 loss in 1Q 2021)

Cardlytics, Inc. Provides Earnings Guidance for the Year 2022

No longer forecast to breakeven

Cardlytics, Inc. Appoints Jose Singer as Chief Product Officer

Cardlytics, Inc. to Report Q1, 2022 Results on May 02, 2022

Cardlytics, Inc., Annual General Meeting, May 24, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

No longer forecast to breakeven

Now 20% undervalued after recent price drop